10-Q: GoodRx Holdings Reports Q1 2025 Results: Revenue Up, Net Income Positive Amidst Retail Pharmacy Landscape Shifts

Sentiment:

Quarterly Report 7 May 2025 4:50 PM

GoodRx Holdings, Inc. reports a 3% increase in revenue and a return to net income profitability for the first quarter of 2025, navigating changes in the retail pharmacy sector.

Summary

GoodRx Holdings, Inc. reported its Q1 2025 financial results, showing a 3% increase in revenue to $203.0 million compared to $197.9 million in Q1 2024.
The company achieved a net income of $11.1 million, a significant improvement from the net loss of $1.0 million in the same period last year.
Adjusted EBITDA increased to $69.8 million, representing a 34.4% margin, compared to $62.8 million and a 31.7% margin in the prior year.
Prescription transactions revenue grew by 2% to $148.9 million, driven by improved unit economics, but was partially offset by a 4% decrease in Monthly Active Consumers.
Subscription revenue decreased by 7% to $21.0 million, primarily due to the sunset of the Kroger Rx Savings Club.
Pharma manufacturer solutions revenue increased by 17% to $28.6 million, driven by organic growth and expanded market penetration.
The company repurchased 23.3 million shares of Class A common stock for $100.9 million during the quarter.
GoodRx acquired substantially all of the assets and assembled workforce of VCRx for $30.0 million in cash on January 13, 2025.
The company is facing challenges due to changes in the retail pharmacy landscape, including store closures and renegotiations between pharmacies and PBMs.

Sentiment

Score: 7

Explanation: The sentiment is cautiously optimistic. While the company achieved profitability and revenue growth, it faces significant challenges in the changing retail pharmacy landscape and ongoing legal proceedings. The growth in pharma manufacturer solutions is a positive sign, but the decline in Monthly Active Consumers is a concern.

Positives

GoodRx achieved a return to profitability with a net income of $11.1 million.
Adjusted EBITDA and Adjusted EBITDA Margin improved year-over-year.
Pharma manufacturer solutions revenue experienced strong growth, indicating successful market penetration.
The acquisition of VCRx expands the company's consumer reach in the prescription transactions offering.
The company continues to execute its stock repurchase program, returning capital to shareholders.
Improved unit economics related to contracting with customers and partners and sales mix drove prescription transaction revenue.

Negatives

Monthly Active Consumers decreased by 4%, reflecting challenges in the retail pharmacy landscape.
Subscription revenue declined due to the sunset of the Kroger Rx Savings Club.
The company faces potential adverse impacts from store closures and renegotiations between pharmacies and PBMs.
Legal settlement expenses related to class action litigation continue to impact financial results.

Risks

Changes in the U.S. retail pharmacy landscape, including store closures and bankruptcies, could negatively impact prescription volume and revenue.
Renegotiations between pharmacies and PBMs may affect retailer reimbursement models and prescription transactions revenue.
Ongoing legal proceedings, including consumer privacy class actions and securities class actions, could result in significant expenses and diversion of resources.
General economic factors, natural disasters, or other unexpected events may adversely affect the business and financial performance.
The company's reliance on a limited number of industry participants, including PBMs, pharmacies, and pharma manufacturers, poses a concentration risk.
Failure to comply with applicable data protection, privacy and security, advertising and consumer protection laws, regulations, standards, and other requirements could lead to penalties and reputational damage.

Future Outlook

The company expects pharma manufacturer solutions to grow as a percentage of total revenue in the near to medium term. They also anticipate a year-over-year decline in Monthly Active Consumers in the near term due to changes in retail pharmacy reimbursement models. The company believes that its net cash provided by operating activities and cash on hand will be adequate to meet its operating, investing and financing needs for at least the next twelve months.

Management Comments

We exited the first quarter of 2025 with over 7 million prescription-related consumers that used GoodRx across our prescription transactions and subscription offerings.

Industry Context

The report highlights the rapid changes in the U.S. retail pharmacy landscape, including store closures and bankruptcies, and their potential impact on GoodRx's business. The company is adapting to these changes by focusing on unit economics and expanding its pharma manufacturer solutions offering.

Comparison to Industry Standards

It's difficult to directly compare GoodRx's results to specific industry standards without more granular data on competitors.
However, the growth in pharma manufacturer solutions revenue aligns with the broader trend of pharmaceutical companies increasing their investment in digital marketing and patient engagement strategies.
The decline in Monthly Active Consumers reflects the challenges faced by many companies in the healthcare space due to changing consumer behavior and increased competition.
Companies like SingleCare and Optum Perks also operate in the prescription savings market, but their specific financial results are not always directly comparable due to differences in business models and reporting practices.
The company's focus on Adjusted EBITDA Margin is a common metric used in the tech and healthcare industries to assess profitability and operational efficiency.

Legal Proceedings

GoodRx is involved in several legal proceedings, including consumer privacy class actions, a securities class action, derivative lawsuits, and consumer state litigations.
The company has reached a settlement agreement with the NDCA plaintiffs for $25.0 million, subject to court approval on June 12, 2025.
The company intends to vigorously defend against the claims asserted in the securities class action, derivative lawsuits, and consumer state litigations.

Related Party Transactions

In March 2025, GoodRx repurchased 20.0 million shares of Class A common stock from related parties, Francisco Partners, Idea Men, LLC and Spectrum, for an aggregate consideration of $84.9 million.

Stakeholder Impact

Shareholders: The return to profitability and stock repurchase program are positive for shareholders.
Employees: The company's restructuring and cost reduction efforts may impact employees.
Customers: The changes in the retail pharmacy landscape may affect the availability and pricing of prescriptions for customers.
Suppliers: The company's relationships with PBMs, pharmacies, and pharma manufacturers are crucial to its business model.

Next Steps

The company will continue to monitor and adapt to changes in the retail pharmacy landscape.
GoodRx will focus on expanding its pharma manufacturer solutions offering.
The company will defend against ongoing legal proceedings.
The company will seek court approval for the settlement agreement with the NDCA plaintiffs on June 12, 2025.

Key Dates

Date	Description
2011-09	GoodRx, Inc. initially formed.
2015-09	GoodRx Holdings, Inc. was incorporated.
2019	Original Office Lease date between Landlord and Tenant.
2020-08-14	First Amendment to Office Lease.
2020-09-25	GoodRx completed its IPO.
2021-05-27	Second Amendment to Office Lease.
2022-01-01	Third Amendment to Office Lease.
2023-02	GoodRx initiated arbitration against Famulus Health, LLC.
2023-10-27	Six plaintiffs filed a class action complaint (SDFL Class Action Matter) against GoodRx in the United States District Court for the Southern District of Florida.
2024-02-07	Fourth Amendment to Office Lease.
2024-02-15	An arbitration award was rendered, which included a damages award and a permanent injunction (the Arbitration Award).
2024-02-23	Board authorized the repurchase of up to an aggregate of $250.0 million of our Class A common stock through February 23, 2024.
2024-02-27	Board approved a new stock repurchase program which authorized the repurchase of up to an aggregate of $450.0 million of our Class A common stock with no expiration date.
2024-03	GoodRx repurchased 14.6 million and 6.2 million shares of our Class A common stock from related parties, Francisco Partners IV, L.P. and Francisco Partners IV-A (collectively, Francisco Partners) and Spectrum Equity VII, L.P., Spectrum VII Investment Managers Fund, L.P., and Spectrum VII Co-Investment Fund, L.P. (collectively, Spectrum) , respectively, for an aggregate repurchase of 20.9 million shares of our Class A common stock at a price of $7.19 per share.
2024-04-22	Lisa Marie Barsuli, individually and on behalf of all others similarly situated, filed a class action lawsuit against GoodRx and certain of our executive officers in the United States District Court for the Central District of California.
2024-05-28	The Bert and Annette Mullens Foundation filed a lawsuit against GoodRx in Pope County, Arkansas, alleging that GoodRx violated an Arkansas statute related to the distribution of health-related discount cards.
2024-06-11	The Minnesota Teamsters Service Bureau, also filed a lawsuit against GoodRx in Hennepin County, Minnesota, alleging that GoodRx violated a Minnesota statute related to the distribution of health-related discount cards.
2024-07	Kroger Rx Savings Club powered by GoodRx sunset.
2024-07-25	U.S. District Judge Andr Birotte Jr. appointed The Kalmanson Family as the lead plaintiff and approved selection of lead plaintiff's counsel.
2024-09-11	The DSC entered an opinion and order denying Famuluss motion to vacate the Arbitration Award and granting our motion to confirm the Arbitration Award as modified by the DSC.
2024-11-19	GoodRx filed a motion to dismiss the class action lawsuit.
2024-11-25	GoodRx entered into a settlement agreement, with the NDCA plaintiffs for $25.0 million , subject to approval by the court on June 12, 2025.
2024-12-02	GoodRx filed a motion to dismiss the complaint, which was denied on December 2, 2024.
2024-12-04	On December 3, 2024, the SDFL plaintiffs filed a voluntary motion to dismiss, with prejudice, which was approved by the court on December 4, 2024.
2024-12-17	GoodRx filed a motion to dismiss the complaint, which was denied on December 17, 2024.
2024-12-20	Plaintiffs in the derivative lawsuits agreed to consolidate the cases and stay the action pending the resolution of the securities class action's motion to dismiss.
2025-01-02	Fifth Amendment to Office Lease Agreement by and between GoodRx, Inc. and Pen Factory Property Owner, LLC.
2025-01-10	The plaintiffs filed their opposition to our motion to dismiss, and we filed our response on February 11, 2025.
2025-01-10	The parties participated in mediation on January 10, 2024, and agreed to participate in an additional day of mediation, which occurred on March 7, 2024.
2025-01-13	GoodRx acquired substantially all of the assets and assembled workforce of VCRx, a prescription savings business of Vivid Clear Rx, Inc., for $30.0 million in cash.
2025-02-11	GoodRx filed our response on February 11, 2025.
2025-02-20	The court granted the stipulation and consolidated the cases under Case No. 2:24-cv-04301-AB-JPR.
2025-03-07	The parties participated in mediation on January 10, 2024, and agreed to participate in an additional day of mediation, which occurred on March 7, 2024.
2025-03-16	GoodRx repurchased 10.0 million , 7.0 million , and 3.0 million shares of our Class A common stock from related parties, Francisco Partners, Idea Men, LLC and Spectrum , respectively, for an aggregate repurchase of 20.0 million shares of our Class A common stock at a price of $4.20 per share.
2025-04-16	GoodRx entered into a non-cancellable office lease agreement in New York, New York that extended the lease term of an existing space and provided for a new space, both of which end in early 2036.
2025-04-23	The court granted our motion to dismiss the securities class action lawsuit, without prejudice and with leave to amend.
2025-04-29	As of April 29, 2025 , the registrant had 100,300,165 shares of Class A common stock, $0.0001 par value per share, and 256,869,320 shares of Class B common stock, $0.0001 par value per share, outstanding.
2025-05	In early May 2025, Rite Aid announced its plan to pursue a sale of substantially all of its assets through a voluntary bankruptcy process.
2025-06-12	Settlement agreement with the NDCA plaintiffs for $25.0 million , subject to approval by the court on June 12, 2025.

Keywords

GoodRx, financial results, Q1 2025, prescription transactions, subscription revenue, pharma manufacturer solutions, Adjusted EBITDA, retail pharmacy, stock repurchase, VCRx acquisition, legal proceedings

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.